Related Experiment Video
Updated: Jun 2, 2025
Advanced Animal Model of Colorectal Metastasis in Liver: Imaging Techniques and Properties of Metastatic Clones
Published on: November 30, 2016
Characterization of the genomic landscape in liver oligometastatic NSCLC
Rongxin Liao1, Guangming Yi1,2, Lu Shen3
1Department of Cancer Center, Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Objectives:
Emerging data have shown that local treatment could provide clinical benefit for non-small cell lung cancer (NSCLC) patients with oligometastasis. Liver metastases have the worst prognosis in advanced NSCLC, but the genomic characteristics of liver oligometastasis remain unclear. The aim of our study was to elucidate the molecular features of liver oligometastatic NSCLC.
Methods:
Paired liver metastatic tissue samples and peripheral blood from 32 liver oligometastatic NSCLC patients were concurrently collected for comprehensive genomic analysis using next-generation sequencing.
Results:
A total of 206 mutated genes in 32 patients were detected, with a median of 4 mutations per sample. The most frequent alterations (> 10%) in liver oligometastasis were TP53 (72%), EGFR (50%), RB1 (19%) and SMARCA4 (12%). The co-occurrence rate of TP53 and RB1 in our cohort was significantly higher than that in the TCGA-LUAD cohort. Age, APOBEC, homologous recombination deficiency (HRD) and deficient mismatch repair (dMMR) established the mutational signature of liver oligometastatic NSCLC. The median tumor mutation burden (TMB) was 4.8 mutations/Mb. A total of 78.12% patients harbored at least one potentially actionable molecular alteration that may guide further targeted therapy according to the OncoKB evidence.
Conclusions:
Our study comprehensively delineated the genomic characteristics of liver oligometastatic NSCLC - such findings were helpful to better understand the distinct clinic-biological features of oligometastasis and optimize personalized treatment of this population.
Insights
This study reveals key genomic alterations in liver oligometastatic non-small cell lung cancer (NSCLC). Understanding these molecular features, including TP53 and EGFR mutations, can guide personalized treatment strategies for improved patient outcomes.
Area of Science:
- Oncology
- Genomics
- Translational Medicine
Background:
- Local treatment shows promise for non-small cell lung cancer (NSCLC) patients with oligometastasis.
- Liver metastases in advanced NSCLC carry a poor prognosis, yet their genomic landscape is poorly understood.
- Elucidating the molecular features of liver oligometastasis is crucial for improving treatment strategies.
Purpose of the Study:
- To characterize the genomic landscape of liver oligometastatic non-small cell lung cancer (NSCLC).
- To identify prevalent gene mutations and mutational signatures in this specific patient subgroup.
- To explore potential actionable molecular alterations for targeted therapy.
Main Methods:
- Comprehensive genomic analysis using next-generation sequencing.
- Paired liver metastatic tissue and peripheral blood samples collected from 32 NSCLC patients with liver oligometastasis.
- Analysis included gene mutations, mutational signatures (APOBEC, HRD, dMMR), and tumor mutation burden (TMB).
Main Results:
- Identified 206 mutated genes across 32 patients, with TP53 (72%), EGFR (50%), RB1 (19%), and SMARCA4 (12%) being the most frequent.
- Observed a significantly higher co-occurrence rate of TP53 and RB1 compared to TCGA-LUAD data.
- Found that 78.12% of patients had actionable molecular alterations, suggesting potential for targeted therapies.
Conclusions:
- The study provides a comprehensive genomic profile of liver oligometastatic NSCLC.
- These findings enhance understanding of the unique clinic-biological features of oligometastasis.
- The identified genomic characteristics can inform personalized treatment strategies for this patient population.
